Sokal E.M.Goldstein D.Ciocca M.Lewindon P.YEN-HSUAN NISilveira T.Sibal A.Dhawan A.MacK C.Bucuvalas J.2020-12-282020-12-2820080277-2116https://www.scopus.com/inward/record.uri?eid=2-s2.0-56049117209&doi=10.1097%2fMPG.0b013e318181b21c&partnerID=40&md5=ebf1cc0dc6f2a0e259c75522bb2402d6https://scholars.lib.ntu.edu.tw/handle/123456789/534202[SDGs]SDG3beta adrenergic receptor blocking agent; cyclophosphamide; interleukin 2 receptor antibody; liver enzyme; prednisolone; prednisone; rapamycin; rituximab; tacrolimus; thymocyte antibody; immunosuppressive agent; aneurysm; bleeding; clinical evaluation; clinical feature; clinical protocol; follow up; hepatocyte transplantation; hepatopulmonary syndrome; human; immunosuppressive treatment; liver disease; liver ischemia; liver necrosis; liver transplantation; metabolic disorder; patient care; patient compliance; patient referral; portoenterostomy; postoperative period; practice guideline; priority journal; recurrent abortion; register; retransplantation; review; spleen artery; stem cell transplantation; treatment failure; treatment outcome; varicosis; child; conference paper; consensus development; liver failure; methodology; patient selection; postoperative complication; stem cell transplantation; Child; Humans; Immunosuppressive Agents; Liver Failure; Liver Transplantation; Patient Selection; Postoperative Complications; Stem Cell Transplantationreview10.1097/MPG.0b013e318181b21c186648822-s2.0-56049117209